Michalek IM, Loring B, John SM. A systematic review of worldwide epidemiology of psoriasis. J Eur Acad Dermatol Venereol. 2017;31(2):205–12.

Article  PubMed  CAS  Google Scholar 

Parisi R, Symmons DP, Griffiths CE, Ashcroft DM, Identification P et al. Global epidemiology of psoriasis: a systematic review of incidence and prevalence. J Invest Dermatol. 2013;133(2):377–85.

Rachakonda TD, Schupp CW, Armstrong AW. Psoriasis prevalence among adults in the United States. J Am Acad Dermatol. 2014;70(3):512–6.

Article  PubMed  Google Scholar 

Armstrong AW, Read C. Pathophysiology. Clinical presentation, and treatment of psoriasis: a review. JAMA. 2020;323(19):1945–60.

Article  PubMed  CAS  Google Scholar 

Boehncke WH, Schon MP. Psoriasis. Lancet. 2015;386(9997):983–94.

Article  PubMed  CAS  Google Scholar 

Drakos A, Torres T, Vender R. Emerging oral therapies for the treatment of psoriasis: A review of pipeline agents. Pharmaceutics. 2024;16(1):111.

Article  PubMed  PubMed Central  CAS  Google Scholar 

Torphy TJ. Phosphodiesterase isozymes: molecular targets for novel antiasthma agents. Am J Respir Crit Care Med. 1998;157(2):351–70.

Article  PubMed  CAS  Google Scholar 

Fertig BA, Baillie GS. Pde4-mediated cAMP signalling. J Cardiovasc Dev Dis. 2018;5(1): 8.

PubMed  PubMed Central  Google Scholar 

Torres T, Puig L. Apremilast. A novel oral treatment for psoriasis and psoriatic arthritis. Am J Clin Dermatol. 2018;19(1):23–32.

Article  PubMed  Google Scholar 

Fala L. Otezla (Apremilast), an oral PDE-4 inhibitor, receives FDA approval for the treatment of patients with active psoriatic arthritis and plaque psoriasis. Am Health Drug Benefits. 2015;8(Spec Feature):105–10.

PubMed  PubMed Central  Google Scholar 

O’Toole A, Gooderham M. Topical roflumilast for plaque psoriasis. Skin Therapy Lett. 2023;28(5):1–4.

PubMed  Google Scholar 

Page MJ, McKenzie JE, Bossuyt PM, Boutron I, Hoffmann TC, Mulrow CD, et al. The PRISMA 2020 statement: an updated guideline for reporting systematic reviews. BMJ. 2021;372:n71.

Article  PubMed  PubMed Central  Google Scholar 

National Heart L, Institute B. Quality Assessment of Clinical trials. 2014.

National Heart L, and Blood Institute. Quality Assessment Tool for Before-After (Pre-Post) Studies With No Control Group. 2014.

L. National Heart aBI. Quality Assessment Tool for Observational Cohort and Cross-Sectional Studies. 2014.

Murad MH, Sultan S, Haffar S, Bazerbachi F. Methodological quality and synthesis of case series and case reports. BMJ Evidence-Based Medicine. 2018;23(2):60–3.

Article  PubMed  PubMed Central  Google Scholar 

Gyldenløve M, Meteran H, Sørensen JA, Fage S, Yao Y, Lindhardsen J, et al. Efficacy and safety of oral roflumilast for moderate-to-severe psoriasis—a randomized controlled trial (PSORRO). Lancet Reg Health. 2023. https://doi.org/10.1016/j.lanepe.2023.100639.

Article  Google Scholar 

Gyldenlove M, Sorensen JA, Thomsen SF, Fage S, Iversen L, Skov L, et al. Improvements in patient-reported outcomes with oral Roflumilast for psoriasis: results from a randomized controlled trial (PSORRO). J Eur Acad Dermatol Venereol. 2025;39(5):e394–7.

Article  PubMed  Google Scholar 

Saadi DG, El-Komy MHM, Khedr H, Shawky N, Hegazy AA, Azzazi Y, et al. A randomized, controlled pilot study of oral roflumilast compared with intramuscular methotrexate for plaque and scalp psoriasis. J Am Acad Dermatol. 2024;90(5):1063–5.

Article  PubMed  CAS  Google Scholar 

Gyldenlove M, Nissen CV, Stave SDW, Thomsen SF, Egeberg A, Loft N. Oral roflumilast in patients with psoriasis: a real-world cohort study. Am J Clin Dermatol. 2025;26(1):147–50.

Article  PubMed  Google Scholar 

Lasheras-Pérez MA, Peñuelas-Leal R, Sanchez-Carazo JL, Sahuquillo-Torralba AJ, Magdaleno-Tapial J, Torres-Navarro I, et al. Treatment of palmoplantar psoriasis with oral roflumilast: a case series. Clin Exp Dermatol. 2024;49(11):1455–7.

Article  PubMed  Google Scholar 

Egeberg A, Meteran H, Gyldenlove M, Zachariae C. Complete clearance of severe plaque psoriasis with 24 weeks of oral roflumilast therapy. Br J Dermatol. 2021;185(6):1251–2.

Article  PubMed  CAS  Google Scholar 

Gyldenlove M, Meteran H, Zachariae C, Egeberg A. Long-term clearance of severe plaque psoriasis with oral Roflumilast. J Eur Acad Dermatol Venereol. 2023;37(3):e429–30.

Article  PubMed  Google Scholar 

Warren RB, Strober B, Silverberg JI, Guttman E, Andres P, Felding J, et al. Oral orismilast: efficacy and safety in moderate-to-severe psoriasis and development of modified release tablets. J Eur Acad Dermatol Venereol. 2023;37(4):711–20.

Article  PubMed  CAS  Google Scholar 

Warren RB, French LE, Blauvelt A, Langley RG, Egeberg A, Mrowietz U, et al. Orismilast in moderate-to-severe psoriasis: efficacy and safety from a 16-week, randomized, double-blinded, placebo-controlled, dose-finding, and phase 2b trial (IASOS). J Am Acad Dermatol. 2024;90(3):494–503.

Article  PubMed  CAS  Google Scholar 

NCT05268016. Meiji Seika Pharma Presents Positive Findings from Phase II Study of ME. 3183, Novel Highly-Potent Selective PDE4 Inhibitor, in Patients With Plaque Psoriasis at EADV Congress 2023 [Available from: https://kommunikasjon.ntb.no/pressemelding/18009237/meiji-seika-pharma-presents-positive-findings-from-phase-ii-study-of-me3183-novel-highly-potent-selective-pde4-inhibitor-in-patients-with-plaque-psoriasis-at-eadv-congress-2023?publisherId=90063

Hashim PW, Chima M, Kim HJ, Bares J, Yao CJ, Singer G, et al. Crisaborole 2% ointment for the treatment of intertriginous, anogenital, and facial psoriasis: a double-blind, randomized, vehicle-controlled trial. J Am Acad Dermatol. 2020;82(2):360–5.

Article  PubMed  CAS  Google Scholar 

Eichenfield LF, Tarabar S, Forman S, Garcia-Bello A, Feng G, Fetterly G, et al. Efficacy and safety of PF-07038124 in patients with atopic dermatitis and plaque psoriasis: a randomized clinical trial. JAMA Dermatol. 2024;160(2):156–63.

Article  PubMed  Google Scholar 

Wang H, Peng MS, Chen Y, Geng J, Robinson H, Houslay MD, et al. Structures of the four subfamilies of phosphodiesterase-4 provide insight into the selectivity of their inhibitors. Biochem J. 2007;408(2):193–201.

Article  PubMed  PubMed Central  CAS  Google Scholar 

Donders Z, Skorupska IJ, Willems E, Mussen F, Broeckhoven JV, Carlier A, et al. Beyond PDE4 inhibition: a comprehensive review on downstream cAMP signaling in the central nervous system. Biomed Pharmacother. 2024;177: 117009.

Article  PubMed  CAS  Google Scholar 

Blauvelt A, Langley RG, Gordon KB, Silverberg JI, Eyerich K, Sommer MOA, et al. Next generation PDE4 inhibitors that selectively target PDE4B/D subtypes: a narrative review. Dermatol Ther (Heidelb). 2023;13(12):3031–42.

Article  PubMed  Google Scholar 

Schafer PH, Adams M, Horan G, Truzzi F, Marconi A, Pincelli C. Apremilast normalizes gene expression of inflammatory mediators in human keratinocytes and reduces Antigen-Induced atopic dermatitis in mice. Drugs R D. 2019;19(4):329–38.

Article  PubMed  PubMed Central  CAS  Google Scholar 

Schafer PH, Truzzi F, Parton A, Wu L, Kosek J, Zhang LH, et al. Phosphodiesterase 4 in inflammatory diseases: effects of Apremilast in psoriatic blood and in dermal myofibroblasts through the PDE4/CD271 complex. Cell Signal. 2016;28(7):753–63.

Article  PubMed  CAS  Google Scholar 

Crowley EL, Gooderham MJ. Phosphodiesterase-4 inhibition in the management of psoriasis. Pharmaceutics. 2023. https://doi.org/10.3390/pharmaceutics16010023.

Article  PubMed  PubMed Central  Google Scholar 

Bhuktar H, Thirupataiah B, Mounika G, Samarpita S, Rithvik A, Sasi Priya SVS, et al. Targeting next-generation PDE4 inhibitors in search of potential management of rheumatoid arthritis and psoriasis. Bioorg Chem. 2024;151: 107689.

Article  PubMed  CAS  Google Scholar 

Takahashi K, Miyake K, Ito J, Shimamura H, Suenaga T, Karasuyama H, et al. Topical application of a PDE4 inhibitor ameliorates atopic dermatitis through Inhibition of basophil IL-4 production. J Invest Dermatol. 2024;144(5):1048–57. e8.

Article  PubMed